ABSTRACT: Conventional clinical management of complex bone healing scenarios continues to result in 5-10% of fractures forming non-unions. Additionally, the aging population and prevalence of osteoporosis-related fractures necessitate the further exploration of novel ways to augment osteogenesis in this special population. This review focuses on the current clinical modalities available, and the ongoing clinical and pre-clinical research to promote osteogenesis in segmental bone defects, delayed unions, and osteoporosis. In summary, animal models of fracture repair are often small animals as historically significant large animal models, like the dog, continue to gain favor as companion animals. Small rodents have well-documented limitations in comparing to fracture repair in humans, and few similarities exist. Study design, number of studies, and availability of funding continue to limit large animal studies. Osteoinduction with rhBMP-2 results in robust bone formation, although long-term quality is scrutinized due to poor bone mineral quality. PTH 1-34 is the only FDA approved osteo-anabolic treatment to prevent osteoporotic fractures. Limited to 2 years of clinical use, PTH 1-34 has further been plagued by dose-related ambiguities and inconsistent results when applied to pathologic fractures in systematic human clinical studies. There is limited animal data of PTH 1-34 applied locally to bone defects. Gene therapy continues to gain popularity among researchers to augment bone healing. Non-integrating viral vectors and targeted apoptosis of genetically modified therapeutic cells is an ongoing area of research. Finally, progenitor cell therapies and the content variation of patient-side treatments (e.g., PRP and BMAC) are being studied. Bone has a remarkable capacity for self-renewal and remodeling, 1 and has evolved to serve many mechanical, endocrine, and homeostatic functions.
Bone has a remarkable capacity for self-renewal and remodeling, 1 and has evolved to serve many mechanical, endocrine, and homeostatic functions. 2 Although normal bone remodels in response to adverse conditions such as changing biomechanical forces, microdamage, and fracture, about 5-10% of fractures do not heal conventionally even with clinical interventions resulting in non-union. 3 Thus, there is an unmet clinical need for novel approaches to promote rapid repair of complicated long bone fractures and large bone defects. The degree of soft tissue injury and type of fixation utilized, host factors such as age, diabetes, NSAID use, and osteoporosis limit osteogenesis in vivo; often these limiting factors result in clinical sequelae such as increased infection rate, risk of nonunion, and inability to maintain quality of life. 4, 5 Increasing osteogenesis has been explored through targeted overexpression of growth factor and exogenous hormone delivery-therapeutics mainly aimed at osteoinduction, a substance that results in the commitment of progenitor cells down an osteoblastic lineage. One way osteogenic induction is achieved in vivo is through delivery of growth factors that result in accelerated osteoblast generation from native progenitor cells, and therefore, accelerated bone formation. Bone formation and bone healing can be achieved through various pathways; therefore, a cursory signaling summary of the growth factors to be discussed, BMP-2 and PTH, is provided.
Bone morphogenic proteins, part of the transforming growth factor-b superfamily, induce bone formation through binding complexes of serine threonine kinase receptors to initiate cell signaling. 6 The most studied osteogenic BMPs, 2, 4, and 7 bind the same complex of receptors. 6 Subsequent SMAD 1/5/8 phosphorylation allows nuclear translocation and binding to specific DNA elements to activate transcription of osteoblast-specific genes. 7 Osteogenesis may also occur through activation of TAK-1 and TAB1, which are crucial upstream regulators of MKK its activation of osteogenic gene transcription via p38/MAPK. 8 Both canonical (R-smad) and non-canonical (MKK) osteogenic BMP signaling results in the transcription of RunX2, Dlx5, and Osx. 9 Bone anabolism via PTH occurs through canonical WNT signaling. WNT-PTH crosstalk results in b-catenin stabilization, nuclear translocation, and subsequent transcription of genes to improve bone formation while decreasing bone resorption. Non-canonical WNT bone anabolism is often achieved with planar cell polarity crosstalk and is implicated in PTH 1-34 response to strain and during skeletal morphogenesis. 10 Further discussion of the signaling pathways involved in osteogenesis for bone healing can be reviewed with these references. 3, 8, 11 and the use of progenitor cells are discussed. Scaffolding materials for bone have recently been comprehensively reviewed and will not be discussed in this manuscript. 12, 13 
ANIMAL MODELS
Research in animal models is a critical component for translation to human clinical trials. No perfect model exists that exactly replicates fracture healing in humans; however, animal models may be utilized to answer specific clinical questions. Tables 1 and 2 provides a descriptive summary of common animal model advantages and disadvantages, and Figure 1 provides pictorial representations of common preclinical models and the method most often utilized to study osteogenesis in segmental bone defects.
Mouse models in fracture repair are often utilized because the ability to purchase and or design specific genotypes and phenotypes affords researchers the ability to study cells with specific characteristics. 14 This is often done through genetically manipulated knock out models and inbred strains. 15 Nonetheless, (Table 1) . Similarly, rat bone is also devoid of haversian systems. 16 The rat is a popular model for delayed and non-union fracture repair models, as well as growth factor use in fracture repair. Similar to the mouse, inbred strains of rats may be purchased from commercial vendors, and housing, anesthesia, and pain management are inexpensive compared to large animal models. While it is often assumed inbred rat strains are genetically homogenous, there is some genetic heterogeneity within inbred populations with large variation in the number of single nucleotide repeats (SNPs). 17 How SNP variation within genetically inbred populations affects baseline variation is unknown. Other limitations of the rat include size and decreased elasticity compared to human bones. 18, 19 It is unknown if the lack of haversian systems alters local reaction and nutrient or waste shuttling during pathology ( Table 1) . The rabbit offers similar advantages as the mouse and rat, such as ease of housing, anesthesia, and pain monitoring 20 ; although they too are dissimilar in size and body weight when compared to humans. Compared with mice and rats, rabbits are a more outbred species. This necessitates larger numbers in a given study to reach statistical power and significance because of individual variation. However, rabbit bone contains haversian systems and more closely replicates large animal models of bone structure. Therefore, success in rabbits may predict success in a larger animal model (Table 2) .
When comparing bone composition between human, canine, swine, bovine, ovine, poultry, and rodent bone, canines' most closely resemble human bone composition when ash weight, extractable proteins, and IGF-1 content are considered. 21 Some studies have found that trabecular bone turnover is higher in canines than in humans, and that there is an age-related decrease in the remodeling capabilities. 21 At the microstructure level, the secondary osteon structure and presence of plexiform bone adjacent to periosteum, especially during callus formation, allows canine cortical bone to withstand greater compressive forces than human bone. 22 Finally, the increased standing of canines as companion animals increases ethical Figure 1 . Figure 1 describes common animal models, the corresponding segmental defect size, and the type of fracture stabilization utilized for segmental bone research.
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concerns for their continued use in orthopedic research (Table 2) . Sheep are more similar in body weight to humans compared to the models discussed thus far, and the dimensions of their bones allow them to be suitable for surgical implants and biomaterial studies. However, their long bone trabecular density is 1.5-2 times greater than humans, conferring more inherent mechanical strength; and, because they are quadrupeds, weight distribution is dissimilar to humans. 22 Despite these limitations, sheep have some advantages. For example, when sheep age, their bone physiology resembles that of humans, with increases in osteoporotic or osteopenic bone loss. 22, 23 Differences in bone healing as it relates to age in sheep, and stark difference in nutrition status should be taken into careful consideration when researchers are considering the sheep as a large animal model for bone repair ( Table 2) .
The horse is an FDA recommended model for osteoarthritis and comparative joint research, 24 and availability to measure in vivo bone strain as well as the similar haversian remodeling suggest the horse is a good pre-clinical model for fracture repair despite cost-associated drawbacks. 25, 26 However, horses exhibit rapid periosteal expansion with plexiform bone that is unlike fracture healing in humans 27 (Table 2 ) and the use of minimally weight bearing metacarpal bones should be considered ( Figure 1 ).
References for Table 1: 21,22,28,29
References for Table 2: 16,20-22,28-30
RECOMBINANT PROTEINS
Recombinant protein therapy is the use of purified therapeutic protein applied to bone defects to produce union (e.g., rhBMPs) or administered systemically to increase osteo-anabolism (e.g., PTH1-34 
BMP-2
In 1965, Marshall Urist first discovered that proteins within bone could induce osteoid formation when he placed demineralized bone matrix in muscle tissue. 35 The proteins that were able to induce osseous metaplasia were given the family name "Bone Morphogenic Proteins." Since the advent of gene sequencing, BMPs have been further characterized by nucleotide similarity and are thus grouped accordingly (e.g., BMP-2/4 and BMP-5/6/7/8). 36 The most potent osteoinductive agent available to clinicians' today is BMP-2. Table 3 summarizes seminal studies that supported FDA approval of rhBMP-2 for open tibial fractures. RhBMP-2 is most commonly combined with bovine collagen 37 and provides an exogenous supraphysiologic dose of osteoinductive growth factor to overcome the challenging clinical environment it is often placed in (e.g., open tibial fractures).
Despite the use of supraphysiologic doses, results are variable. 38 Contributing factors include the short halflife, potential for improper folding or post-translational modification that can reduce biologic activity, 39 and the presence of natural BMP-2 antagonists, such as Noggin. 40 Likewise, there are strong species-associated dose requirements for osteogenesis-the recommended dose to induce osteogenesis in humans (1.5 mg/ml) is at least 3.75 times greater than the required dose in rodents (0.02-0.4 mg/ml). 41 Furthermore, rhBMP-2 therapy is complicated as it is often cost-prohibitive, is not covered by insurance, 42 is associated with a high degree of inflammation and ectopic bone formation, 43 and widespread off-label use is documented and often results in unwanted side effects.
44,45
RhBMP-2 use often results in bony union, but continuous corticies and non-remodeled trabeculae are often thin 46 ; as the ultimate goal of fracture healing is to have mechanically functional bone, rhBMP-2 generated bone quality is in question. Osteolysis and subsistence are reported in spinal fusion 47-49 -although, spinal use of rhBMP-2 is beyond the scope of this review, it is prudent to note similar findings found in long-bone fracture repair-principally cystic bone formation. There are accounts of greater trabecular bone spacing 50 and evidence of BMP-2 signaling induced osteoclastogenesis and inflammatory cytokine expression induction 51-53 -traits not overcome, and potentially worsened, by supraphysiologic rhBMP-2 doses. There are reports of BMP-2 induced adipogenesis 54 and clinical accounts of adipose tissue scattered throughout BMP-2 regenerated bone. 55 Although the concentration of BMP-2 required to overcome its native antagonists is unknown, the current research trends to low-dose BMP-2 with moderate success. 56, 57 Furthermore, phase II and III clinical trials were completed with objectives to decrease the dose of rhBMP-2 from 1.5 to 1.0 mg/ml in patients undergoing internal fixation surgeries to repair closed diaphyseal tibial fractures. To its favor, retrospective analyses of on-label spinal fusion and open tibial fracture surgeries show a decreased rate of secondary interventions when rhBMP-2 is used instead of autograft alone. Additionally, operation time and hospital stay were reduced with rhBMP-2 use. 38, 58 There is no current consensus on rhBMP-2 treatment, utilization, or effectiveness among clinicians or researchers. Further study is needed to elucidate if combination therapy may allow a lower dose of rhBMP-2, if rhBMP-2 could be more effective if CHALLENGES OF PROMOTING OSTEOGENESIS administered via another mechanism (e.g., gene therapy), and if bone quality and subsistence limit the long-term effectiveness of treatment.
PTH 1-34
The production of recombinant PTH 1-34, teriparatide, the amino terminal of the full-length PTH peptide (84 amino acids), is utilized to encourage osteo-anabolism when administered systemically and intermittently for the treatment of osteoporosis. Off-label, PTH (1-34) has been studied in clinical trails to assess fracture repair 59 ; however, therapy is limited by dosing ambiguities and mixed results. In one human clinical trial treating distal radius fractures, a higher dose (40 mg) of PTH 1-34 was no better than the vehicle control, while the lower dose (20 mg) shortened time to cortical continuity. 59 In patients with pelvic fractures, a dose of 100 mg of PTH and concurrent vitamin D and calcium supplementation accelerated fracture healing and functional outcome. 60 In rat tibial fractures, lower doses (60 mg) of PTH 1-34 produced less external callus volume and ultimate load when compared to higher doses (200 mg).
61 These ambiguities and mixed results have led to the termination of several of the clinical trials in long bone fracture repair; although, PTH (1-34) may still be clinically indicated in other clinical scenarios. For instance, PTH (1-34) increases bone formation around implants, helping them assimilate into grafts [62] [63] [64] [65] and increases flexural thickness and overall cortical thickness 66 predominantly through the proliferation of bone lining cells 67 and inhibition of osteoblast apoptosis. 68 It may also regulate bone formation around bone implants through strain specific osteoblastic induction. 10 An important limitation of PTH (1-34) is that it that treatment is approved for only 24 months of use due to an increased incidence of osteosarcoma and a doserelated increase in osteoblastoma and osteoma in female and male Fischer rats (https://www.accessdata. fda.gov/drugsatfda_docs/label/2008/021318s015lbl.pdf). While this limitation may not be relevant in long bone fracture since patients should be well-within healthy bone remodeling, patients at risk of osteoporotic fractures may require long-term therapy.
References for Table 3: 30-32,61,69-87
GENE THERAPY
The transformation of cells, as observed by differing phenotypes, dates back to at least 1928, and was first observed and characterized in bacteria by Frederick Griffith. 88 Today, the term gene therapy encompasses a variety of techniques that utilize viruses, plasmids, and gene activated matrices to deliver therapeutic cDNA into host cells. This review will focus on gene therapy utilizing viruses only. Targets of gene therapy may be somatic or germ cells, and the distinction is important as the FDA currently allows gene therapy on somatic cells only. In challenging bone-healing environments it would be beneficial to deliver therapeutic osteo-anabolic genes over several weeks as opposed to only a few days.
The purpose of viral gene therapy is to either (i) replace defective native gene sequence, or to (ii) provide an extra gene copy and drive over expression. Although different vectors and their associated therapies are designed with specific therapeutic targets in mind, transduction should result in transgene expression at therapeutic quantities 89 and be highly specific to the cellular target. 90 Viral gene therapy utilizes the 92 Gene therapy to induce bone formation has been delivered in vivo directly to a defect as a suspension, 93, 94 in vivo lyophilized to an allograft implant scaffold, 95 or through an ex vivo approach, where cell-type transduction is controlled in vitro, and then applied to a defect some time later in a dual surgery process (traditional), 89, 96 or tissue may be selectively isolated, transduced, and re-implanted in a single surgery (expedited). 91, 97, 98 Figure 2 shows how a traditional, allogeneic ex vivo approach might be utilized to study fracture repair in situ.
Therapeutic genes used in gene therapy were initially successful in their use as recombinant proteins, and were then explored with gene therapy because it was hypothesized they may better effect clinical success with an alternate delivery. 99 At the site of large bone defects, recombinant proteins require specific temporal and spatial delivery mechanisms to decrease diffusion of the protein from the site of interest. While genetically modified cells will produce protein that also diffuses, the continuous and persistent production that is achieved for the lifetime of the genetically modified cell eliminates the need to deliver one-time supraphysiologic doses as occurs with recombinant protein therapy. Further, transduction and gene production by host cell machinery is more likely to undergo genuine post-translational modification, and may have greater biological activity compared to their recombinant counterparts. 39, 100 Despite removal of virulence factors from therapeutic vectors, there is concern viruses may revert to pathogenicity if they transduce a cell that has previously been, or becomes co-infected with another virus and that allows pathogenic replication within the patient. Some vectors, especially commonly used adenoviruses are pro-inflammatory even after removal of virulence factors, a trait attributed to the production of non-therapeutic, non-pathogenic viral genes. 101, 102 The following viruses have been the most commonly used in segmental bone defects as delivery vectors. Table 4 provides seminal gene therapy references utilizing BMP-2 and PTH (1-34) as therapeutics for segmental bone defects.
Adeno Vectors
The non-enveloped adenovirus is a double stranded DNA (dsDNA) virus. Several of the early transcript genes of adenovirus are required for adeno-associated vectors to replicate, although the two are unrelated. Adenoviruses are relatively ubiquitous and do not cause any known disease in humans, making them incredibly useful during the early experiments of gene therapy. However, adenoviruses do elicit a large immune response, leading to immune destruction of transduced target cells. 103, 104 Newer vector constructs are often utilized.
Adeno-Associated Vectors
The adeno-associated virus (AAV) is a small, singlestranded DNA parvovirus that elicits minimal immunogenic reaction. The many serotypes available add to its allure as a therapeutic vector since targeted tissue tropism is conferred. 90 Serotype 2 is the most commonly utilized serotype in musculoskeletal tissues and is used with serum free media for maximal transduction. Several genes including BMP-2, 105 BMP-4, 106 and BMP-7 107 are used in AAV vectors to induce osteogenesis, although BMP-2 is by far the most widely used due to its ability to induce de novo osteogenesis in vitro 108 and in vivo. 109 However, it has been observed that AAV vectors might not produce enough protein to heal large segmental defects. As previously mentioned, AAV vectors utilize genes from Adenovirus (termed "helper genes") to ensure viral replication; although, high titers of recombinant adeno-associated viral vectors have been produced in the absence of adenovirus helper genes.
110
Self-Complementary Adeno-Associated Vectors Self-complementary adeno-associated virus (scAAV) is an AAV vector that has been engineered to contain coding and non-coding strands of DNA. Therefore, Figure 2 . Figure 2 describes how an ex vivo technique may be utilized with cryopreservation to provide a gene therapy approach to segmental bone defects in fracture repair.
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scAAV does not require DNA polymerase to produce a complementary DNA strand before mRNA is produced. This ultimately results in more efficient protein expression. 111 scAAV vectors have been used in vivo to produce the interleukin-1 receptor antagonist (IL-1ra) protein transgene in normal joints 112 ; and it has been shown that repeat dosing can be achieved without immunogenic reaction when the serotype of the repeat dose is modified. 112 In bone healing, scAAV vectors have been used to deliver various DNA molecules that showed improved bone integration histologically. Yazici et al. 95 used scAAV2.5-BMP-2 coated allografts to increase incorporation when compared to autograft. Further, Yazici et al. 95 showed that scAAV-BMP-2 treated femurs had increased torsional rigidity when compared to the control femur in post mortem analysis. In contrast to integrated vectors, scAAV vectors remain episomal within the nucleus and the transgene is not replicated with subsequent cell divisions. Although this may seem like a disadvantage, scAAV transduced cells increased IL-1ra transgene expression in the equine model 183 days after in vivo injection. 112 Therefore, long-term expression results from scAAV gene therapy even though it does not integrate into the cells genome. Figure 2 shows how scAAV may be used clinically to augment bone healing.
Lentiviral Vectors
Lentiviral vectors are RNA viruses that transduce dividing and non-dividing cells, and each virion inserts two transgene copies into host chromosomes. Host chromosome integration leads to prolonged transgene expression, however insertion is currently not controlled and may lead to insertional mutagenesis. Insertional mutagenesis occurs when the viral transgene integrates near potential proto-oncogenes, altering the nuclear regulation of transcripts, and ultimately resulting in unwanted neoplasia. This random insertion into the genome affects the safety profile of this vector 91 and could limit its efficacy; however non-integrating lentiviral vectors have been produced 113, 114 and studies are being performed using antiviral pro-drugs that are metabolized to toxic compounds within transduced cells only. 115 Such advancements in vector technology show an effort to provide a clinical approach to eliminating therapeutic cells after the transgene is no longer needed.
Retroviral Vectors
Retroviral vectors are RNA viruses that preferentially transduce and integrate into the genome of actively dividing cells. While bone is in a constant state of turnover, it is not dividing at a rate that allows it to be In rats, femoral defects were treated with Ad-BMP-2 at the time of defect creation or 24 h after. Mean bending and mean stiffness were increased, and bone mineral content was similar to contralateral control femora. In rabbit ulnae, segmental defects were treated 7 days after defect creation with Ad-BMP-6. At 6 and 8 weeks, treated ulnae had increased bone area, mineral content, and were stronger in torsional stiffness than control ulnae. In the equine, Ad-BMP-2/7 treated metacarpal IV did not heal better than untreated controls BMP-2, BMP-2/7, BMP-6 93, 94, 119, 120 In vivo: GAM In mice, scAAV-BMP-2.5 lyophilized to allograft healed segmental femoral defects, cortical shells formed were equivalent to unfractured femurs and had equivalent torsional rigidity. PTH (1-34) on a collagen sponge increased periosteal bone in equine cortical defects after 13 weeks, but did not heal subchondral defects exposed to the articular surface BMP-2, PTH (1-34) 95, 118 Ex vivo: traditional
Utilizing the traditional ex vivo technique, rat femoral defects treated with LV-BMP-2 had significantly higher peak torque and torque to failure biomechanics than femora treated with BMDMSCs alone.
Further, a variety of cell types including muscle and human adipose can be transduced and utilized in mice and rats to produce bony union after 8 weeks BMP-2, BMP-4 89, 96, 116, 122, 123 Ex vivo: expedited Muscle, fat, and buffy coat hematologic components were transduced the same day as defect creation and implanted into critical sized bone defects. Radiographic union was displayed as early as 10 days and was earlier when compared to ex vivo traditional methods. Within 8 weeks, bone volume and torsion testing suggest mechanical stability comparable to control femora BMP-2, LMP-1 97, 98, 121 CHALLENGES OF PROMOTING OSTEOGENESIS a suitable target of retroviral vectors delivered in vivo. However, similar to lentiviral vectors, transgene expression may also be mutagenic. 116, 117 References for Table 4: 89,93-98,118-123
PROGENITOR/STEM CELLS
The term "stem cell" exists in scientific literature dating back to 1868. Stem cells, or perhaps more correctly, tissue progenitor cells, utilized in modern research are derived from a variety of tissues (e.g., are digested away from lipoaspirate, muscle, blood vessels, and other organs 124, 125 ) and are selected for by adherence to culture plates. To properly denote plastic adherent tissue-based cells isolated from any source as true mesenchymal stem cells, characterization would include expression of CD105, CD73, and CD90. 126 Additionally, cells would lack expression of the following markers: CD45, CD34, CD14/11b, CD79-alpha/ CD19, and Human Leukocyte Antigen-DR, 126 must selfrenew, re-populate, and undergo tri-lineage differentiation in vitro. 127 Ease of isolation, replication potential (telomere length, pluripotent markers), planned therapeutic use, and other clinical indications often dictate the site of progenitor cell harvest, though there is evidence to suggest differences in cell differentiation between progenitor cells from different sources. [128] [129] [130] While each source can undergo tri-lineage differentiation into adipocytes, chondroblasts, and osteoblasts, there is evidence of lineage biases of progenitor cells isolated from bone marrow when osteoinduction is the goal 131 and it is likely epigenetic gene regulation confers some sort of tissue-source memory, as some groups have successfully changed the osteogenic differentiation capacity of adipose derived progenitor cells to rival bone marrow derived progenitors through use of histone deacetylase inhibitors. 132 Patients presenting with several risk factors for nonunion formation or those presenting for a second surgery to repair a failed fracture consolidation are considered to have clinical indications for progenitor cell therapies 133 ; however, patients cannot receive culture-expanded BMDMSCs unless they are part of a clinical trial. In lieu -clinicians are utilizing patient-side progenitor cell therapies, such as bone marrow aspirate concentrate and stromal vascular fraction-increased concentrations of cytokines and a small population of stem cells characterize both treatments. 134 While these patientside treatments are minimally manipulated and autogenic, they have the potential to be heavily influenced by patient co-morbidities.
It [135] [136] [137] although there remains no consensus on how many cells are needed to fill a defect. In general, it is considered that mineralized callus formation is correlated to the number of progenitor cells within the bone marrow aspirate, especially when utilized in the absence of concentration. 138 Therefore, it is reasonable to postulate that culture-expanded cells may be especially helpful in instances of healing segmental bone defects when higher concentrations of cellular therapies have affected clinical success. 139, 140 Bone marrow aspirate concentrate (BMAC) is one minimally manipulated therapy, and considered an alternative to autologous bone graft (ABG). ABG has many well-documented co-morbidities and an upper limit of available graft material. 141 BMAC contains several cell type precursors, including platelet alphagranules that contain numerous growth factors, and a small population of mesenchymal stem cells. 142 Recently, one group found that nucleated cell counts of BMAC samples were not predictive of colony forming units, suggesting the healing property of BMAC is correlated to growth factors contained within platelet granules such VEGF and IL-1ra. 134 In an equine model it was demonstrated that the addition of culture-expanded BMDMSCs and autologous PRP resulted in bone formation in chondral defects. 143 The role of nucleated cells, expanded BMDMSCs, and platelets (and platelet-based patient-side therapies) remains to be elucidated but may have the potential to encourage bone healing. It is judicious to note that none of these therapies have been tested in a challenging bone healing environment.
CONCLUSION
Promotion of osteogenesis to heal segmental bone defects and osteoporosis in humans and animals is a complex issue. While many studies have been performed, there are a myriad of unanswered questions. Successful clinical therapies may predominantly move towards cell-based growth factor delivery systems that address the need for sustained osteoinduction, especially in large defects to augment risk factors for non-unions. The barrier to this may be regulations that are associated with FDA rules governing autologous and allogeneic cell implantation in addition to genetically modified cells. The frequencies of nonunions (5-10% of fractures annually) remain an unmet challenge with serious socioeconomic impact, and the aging population necessitates that a more critical emphasis must be put on osteoporotic fractures and disease progression. Cellular-based therapeutic approaches require further intensive investigation, as there is no clear solution. Future testing in preclinical models and additional clinical trials of bone repair will elucidate safety and efficacy of alterations in dosing and route of administration of the recombinant proteins BMP-2 and PTH 1-34, gene therapy, and progenitor cell therapies.
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